59281-14-0 Usage
Description
5-(benzyloxy)-2-(hydroxymethyl)pyridin-4-ol, also known as BzATP, is a chemical compound belonging to the pyridine family. It is a potent and selective agonist for the P2X7 receptor, a ligand-gated ion channel present in immune cells. BzATP is widely used in research to study the physiological and pathological roles of the P2X7 receptor in inflammation, pain, and neurodegenerative diseases. It is also being investigated as a potential therapeutic target for conditions such as chronic pain, rheumatoid arthritis, and multiple sclerosis. BzATP is known for its ability to induce inflammatory responses and cytokine release through the P2X7 receptor, making it a valuable tool for understanding the role of purinergic signaling in various disease states.
Uses
Used in Pharmaceutical Research:
5-(benzyloxy)-2-(hydroxymethyl)pyridin-4-ol is used as a research compound for studying the P2X7 receptor's role in inflammation, pain, and neurodegenerative diseases. Its agonistic properties allow researchers to investigate the receptor's function and potential therapeutic applications.
Used in Drug Development:
In the pharmaceutical industry, 5-(benzyloxy)-2-(hydroxymethyl)pyridin-4-ol is used as a potential therapeutic target for the development of treatments for chronic pain, rheumatoid arthritis, and multiple sclerosis. Its ability to modulate the P2X7 receptor makes it a promising candidate for the development of new drugs targeting these conditions.
Used in Immunology Research:
5-(benzyloxy)-2-(hydroxymethyl)pyridin-4-ol is used as a tool in immunology research to understand the role of purinergic signaling in immune cell function and inflammatory responses. Its ability to induce cytokine release through the P2X7 receptor helps researchers explore the complex interactions between immune cells and their environment.
Used in Neuroscience Research:
In the field of neuroscience, 5-(benzyloxy)-2-(hydroxymethyl)pyridin-4-ol is used to study the involvement of the P2X7 receptor in neurodegenerative diseases. Its agonistic effects on the receptor provide insights into the potential role of purinergic signaling in the progression of these diseases and the development of therapeutic strategies.
Used in Toxicology Studies:
5-(benzyloxy)-2-(hydroxymethyl)pyridin-4-ol is used in toxicology studies to evaluate the safety and potential side effects of compounds targeting the P2X7 receptor. Its ability to induce inflammatory responses and cytokine release can help researchers assess the risks associated with the development of new drugs and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 59281-14-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,2,8 and 1 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 59281-14:
(7*5)+(6*9)+(5*2)+(4*8)+(3*1)+(2*1)+(1*4)=140
140 % 10 = 0
So 59281-14-0 is a valid CAS Registry Number.
59281-14-0Relevant articles and documents
Development of the Convergent, Kilogram-Scale Synthesis of an Antibacterial Clinical Candidate Using Enantioselective Hydrogenation
Benson, Helen,Bones, Karen,Churchill, Gwydion,Ford, Gair,Frodsham, Lianne,Janbon, Sophie,Millington, Fiona,Powell, Lyn,Raw, Steven A.,Reid, Julie,Stark, Andrew,Steven, Alan
, p. 588 - 598 (2020/05/19)
Early chemical development studies into the best way of assembling AZD9742, an antibacterial drug candidate, have involved swapping the order of two reductive aminations. The orthogonally functionalized aminopiperidine partner for these couplings is now enantioselectively synthesized using ruthenium-catalyzed asymmetric hydrogenation. The challenge of controlling defluorination through an appropriate catalyst choice has hitherto prevented this revised sequence from reaching its full potential. However, it is still shown to allow access to the active pharmaceutical ingredient in a stereochemically pure form and has been demonstrated on a multikilogram scale. The reductive aminations in both the original and revised sequences provided different scale-up challenges, and the solutions implemented are described.
Novel compounds that are inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma
-
, (2020/02/01)
These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections
Tan, Liang,Tao, Yunliang,Wang, Ting,Zou, Feng,Zhang, Shuhua,Kou, Qunhuan,Niu, Ao,Chen, Qian,Chu, Wenjing,Chen, Xiaoyan,Wang, Haidong,Yang, Yushe
, p. 2669 - 2684 (2017/04/21)
Conjugating a siderophore to an antibiotic is a promising strategy to overcome the permeability-mediated resistance of Gram-negative pathogens. On the basis of the structure of BAL30072, novel pyridone-conjugated monosulfactams incorporating diverse substituents into the methylene linker between the 1,3-dihydroxypyridin-4(1H)-one and the aminothiazole oxime were designed and synthesized. Structure-activity relationship studies revealed that a variety of substituents were tolerated, with isopropyl (compound 12c) and methylthiomethyl (compound 16a) showing the best efficacy against multidrug-resistant (MDR) Gram-negative pathogens. In addition, compound 12c exhibits a good free fraction rate in an in vitro human plasma protein binding test, along with a low clearance and favorable plasma exposure in vivo. In a murine systemic infection model with MDR Klebsiella pneumoniae, compound 12c shows an ED50 of 10.20 mg/kg. Taken together, the results indicate that compound 12c is a promising drug candidate for the treatment of serious infections caused by MDR Gram-negative pathogens.
